The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions

Stav Brown, MD*
Tal Brown*
Paul S. Cederna, MD†‡
Rod J. Rohrich, MD§

Summary: The Coronavirus Disease 2019 (COVID-19) pandemic has presented a major threat to public health worldwide alongside unprecedented global economic and social implications. In the absence of a “gold standard” treatment, the rapid development of a safe and effective vaccine is considered the most promising way to control the pandemic. In recent years, traditional vaccine technologies have seemed insufficient to provide global protection against the rapid spread of emerging pandemics. Therefore, the establishment of novel approaches that are independent of whole pathogen cultivation, cost-effective, and able to be rapidly developed and produced on a large scale are of paramount importance for global health. This article summarizes the current efforts to develop a COVID-19 vaccine, including the ongoing and future anticipated clinical trials. We also provide plastic and reconstructive surgeons with insight into the novel technologies currently utilized for COVID-19 vaccine development, focusing on the very promising viral-vector-based and gene-based vaccine technologies. Each platform has its own advantages and disadvantages related to its efficacy and ability to induce certain immune responses, manufacturing capacity, and safety for human use. Once the fundamental key challenges have been addressed for viral-vector-based and gene-based vaccines, these novel technologies may become helpful in winning the fight against COVID-19 and transforming the future of health care.

From the *Sackler School of Medicine at Tel Aviv University, Tel Aviv, Israel; †Department of Biomedical Engineering, University of Michigan, Ann Arbor, Mich.; ‡Section of Plastic Surgery, University of Michigan, Ann Arbor, Mich.; §Dallas Plastic Surgery Institute, Dallas, Tex.

Received for publication June 30, 2020; accepted September 1, 2020.

Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/GOX.0000000000003206

Science knows no country, because knowledge belongs to humanity, and is the torch which illuminates the world.
—Louis Pasteur

INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) pandemic has presented a major threat to public health worldwide alongside unprecedented global economic and social implications. Identified in Wuhan, Hubei Province, China, in December 2019, the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has infected a total of 20,840,381 individuals, causing 754,566 global deaths as of August 14, 2020. An estimated 5,248,722 cases have been confirmed in the United States, and the death toll there has surpassed 160,000. COVID-19 has a relatively high degree of pre-symptomatic transmission, high mortality rate, severe morbidity rate, and relatively long hospitalization period. As a result, the fight against COVID-19 has required extensive interventions such as quarantine, social distancing, isolation of infected populations, border closures, school shutdowns, and extensive lockdowns to contain the virus, “flatten the curve,” and save lives. The COVID-19 pandemic has changed the landscape of plastic surgery, restructured the daily experience of plastic surgery practices, altered the way residents and fellows are trained, substantially impacted research, and revolutionized patient care. The implications of the current COVID-19 pandemic on plastic surgery are summarized in Table 1.

Due to the profound global implications of the COVID-19 crisis, there has been an unprecedented race to develop treatments and vaccines against SARS-CoV-2. Multiple clinical trials are underway to define potential roles for antiviral agents and specific immunomodulators as...
well as passive immunization with convalescent plasma. However, no “gold standard” treatment or prophylactic medication has been approved for COVID-19. Optimizing supportive care for COVID-19 positive patients remains the mainstay of therapy, including oxygen, mechanical ventilation, and treatment of the sequelae and complications. With multiple waves of illness anticipated, and in the absence of approved treatments, the development of a safe and effective vaccine will be a game-changing step in the global fight against COVID-19 and is considered the most promising way to eradicate the virus.

This article summarizes the current efforts to develop a SARS-CoV-2 vaccine, including the ongoing and future anticipated clinical trials. We also provide plastic and reconstructive surgeons with insight into the novel technologies currently utilized for SARS-CoV-2 vaccine development, focusing on the very promising viral-vector-based and gene-based vaccine technologies (Fig. 1).

### VACCINES: IMMUNOLOGICAL PRINCIPLES AND VACCINE DEVELOPMENT STRATEGIES

Since the development of the first vaccine by Dr. Edward Jenner more than 200 years ago, vaccinations have made an enormous contribution to global health. However, the development process for conventional vaccines takes
more than 10 years\textsuperscript{25} and requires 4 Phases,\textsuperscript{26–28} as summarized in Figure 2. Therefore, the lack of time remains a major barrier for safe and effective vaccine development in outbreak situations.

**Immunological Principles of Vaccination**

Immunization can be derived from either passive or active immunization.\textsuperscript{29} Passive immunization occurs with the transfer or administration of already preformed antibodies, providing temporary immunity.\textsuperscript{29} One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from previously infected individuals, which is administered via direct transfusion to COVID-19 patients, in an attempt to confer passive immunity.\textsuperscript{30–34}

Active immunization occurs with the exposure to an antigen and typically produces long-term immunity due to the immune system stimulation.\textsuperscript{29} The immune system is divided into two main subsystems: the innate system, which provides an initial, non-specific response, with no memory induced, and the adaptive system, which provides a later, antigen-specific response and induces immunological memory.\textsuperscript{35} When antigens are introduced into the bloodstream via infection or vaccination, they are captured and processed by Antigen Presenting Cells (APCs), which then display an antigen-derived peptide fragment on their surfaces. APCs then migrate to lymph nodes, and activate T helper cells through a process called “antigenic presentation.” T helper cells stimulate both arms of the adaptive immunity: humoral (antibody-based) and cellular.

Humoral immunity is achieved via differentiation, proliferation, and maturation of B-lymphocytes into antibody-secreting plasma cells and memory lymphocytes of the same antigenic specificity, and cell-mediated

---

**Fig. 2.** Diagram displaying the various phases of a clinical trial.
immunity is achieved via activation of naive cytotoxic T cells to active, antigen-specific cells. 29 The stimulation of both the humoral and cell-mediated arms of the adaptive system by the production of effector cells (plasma B cells for humoral immunity and active cytotoxic T cells for cell-mediated immunity) and memory cells is required to ensure protection upon re-exposure to the same antigen. 35 Figure 3 illustrates the immune stimulation response in detail.

Conventional Vaccine Platforms

The main conventional vaccine technologies include inactivated vaccines (which utilize a killed pathogen), subunit/recombinant vaccines (which utilize specific pieces of the pathogen administered along with adjuvants), toxoid vaccines (pathogen-toxin-based), and live attenuated vaccines. 36 Each platform has its own advantages and disadvantages related to its efficacy, immunogenicity, and ability to induce certain immune responses, manufacturing capacity, and safety for human use, as summarized in Table 2. 36–42

Novel Vaccine Platforms

In recent years, traditional vaccine technologies that consist of working with a virulent pathogen during manufacturing seem insufficient to provide global protection against the spread of emerging pandemics. Therefore, the establishment of novel approaches that are independent of pathogen cultivation (a relatively lengthy and high-risk process), are cost-effective, and could be rapidly developed and produced on a large scale, are of paramount importance for global health. 41

Two promising novel platforms that have generated significant attention in recent years due to their potential use for a variety of applications include the viral-vector-based and gene-based vaccine technologies. Their advantages over conventional approaches highlight the role of these platforms in the new era of vaccinology, as potential game-changers in epidemics and emerging diseases. 43 The strengths and weaknesses of these platforms are summarized in Table 2 and discussed below.

Viral-vector-based Vaccines

Viral vector vaccines use separate, genetically engineered, viruses to carry DNA of target antigens into human cells. The DNA contained in the viral vector encodes antigens that, once expressed in the infected human cells, elicit antigen-specific humoral and cell-mediated immune responses via antigen presentation (Fig. 3). 44 A variety of viruses have been employed as viral vectors, 45 with Adenovirus (Ad) vectors being the most commonly utilized due to their various advantages. Ad vectors’ advantages over other viral vectors include their ability to enter a broad range of target cells in humans, 46 deliver various target antigens and large DNA insertions, 47 and induce potent humoral and cellular responses. 48 However, utilizing an unrelated virus for delivery poses several challenges in terms of manufacturing, safety, and immunogenicity, as summarized in Table 2.

Gene-based Vaccines

Gene-based vaccine platforms consist of genetic sequences in the form of plasmid DNA 49 and mRNA. 50 Once injected intramuscularly (IM), the genetic sequence enters the myocytes 51 to achieve encoding of the desired antigen. 52 The endogenously synthesized antigens are then secreted from myocytes for cross presentation and consecutive stimulation of humoral and cellular responses.

Fig. 3. Illustration depicting the stimulation of humoral and cellular immune responses.
| Platform (Refs)          | No. Clinical Trials | No. Pre-clinical Studies | Platform Status | Advantages                                                                 | Disadvantages                                                                 | Existing Licensed Vaccines                  |
|-------------------------|---------------------|--------------------------|----------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------|
| Inactivated             | 5                   | 9                        | Licensed       | Safety:                                                                   |                                                                                | HAV, influenza (shot only), Polio (shot only), rabies                             |
|                         |                     |                          |                | ◦ Cannot replicate                                                        |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ No adjuvants required                                                   |                                                                                |                                                                              |
|                         |                     |                          |                | **Efficacy:**                                                             |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ High potency                                                            |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Multivalent                                                             |                                                                                |                                                                              |
| Live attenuated virus   | 0                   | 3                        | Licensed       | Safety:                                                                   |                                                                                | Measles, mumps, rubella (MMR combined vaccine), rotavirus, smallpox, chickenpox, yellow fever |
|                         |                     |                          |                | ◦ No adjuvants required                                                   |                                                                                |                                                                              |
|                         |                     |                          |                | **Efficacy:**                                                             |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ High potency                                                            |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Induction of long-lived responses                                       |                                                                                |                                                                              |
| Viral vector            | Non-replicating: 5  | Non-replicating: 19      | Experimental   | Safety:                                                                   |                                                                                | Non-replicating: none                                                               |
|                         | RePLICATING: 1      | RePLICATING: 17          |                | ◦ Favorable safety profile—whole pathogen cultivation not required       |                                                                                | Replicating: dengue fever                                                            |
|                         |                     |                          |                | ◦ No adjuvants required                                                   |                                                                                |                                                                              |
|                         |                     |                          |                | **Efficacy:**                                                             |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Able to induce potent, antigen-specific cellular and humoral immune responses |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Strong innate immune response                                           |                                                                                |                                                                              |
|                         |                     |                          |                | **Production and manufacturing:**                                        |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ High productivity—independent of whole pathogen cultivation             |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ High specificity and accuracy—can be engineered                        |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Easily to accurately express any antigen of choice,                     |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Specific targeting, and processing in the cell                          |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ To antigen delivery as genetic information                              |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ High versatility—allows large insertions in genome and therefore the    |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Development of a large variety of vaccines                              |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Sufficient production capacities for global vaccination                 |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Vaccination due to established high yield production processes with     |                                                                                |                                                                              |
|                         |                     |                          |                | ◦ Means of upscaling                                                      |                                                                                |                                                                              |
### Table 2. (Continued)

| Platform (Refs) | No. Clinical Trials | No. Pre-clinical Studies | Platform Status | Advantages | Disadvantages | Existing Licensed Vaccines |
|-----------------|---------------------|--------------------------|-----------------|------------|---------------|---------------------------|
| Protein Subunit | 7                   | 50                       | Licensed        | Safety: Efficacy: | Requires additional adjuvants Multiple doses are usually required Requires dedicated production processes, facilities and stability assays for each vaccine Multivalent formulation can be challenging | Hib, HBV, HPV, Whooping cough (part of the DTaP combined vaccine), Pneumococcal disease, Meningococcal disease, Shingles |
| RNA             | 6                   | 16                       | Experimental    | Safety: Efficacy: | Potential risk for severe adverse reactions Production and Manufacturing: | None |
| DNA             | 4                   | 12                       | Experimental    | Safety: Efficacy: | Potential long-term persistence, risk of genomic integration, potentially leading to mutagenesis and oncogenesis Potential generation of autoantibodies Potential adverse effects due to cytokines/co-stimulatory molecules expression used to enhance DNA immunogenicity Low immunogenicity in humans Production and Manufacturing: | None |
| Other platforms | 1                   | N/A                      | N/A             | N/A         | N/A           | N/A                       |

DNA, Deoxynucleic acid; DTaP, diphtheria, tetanus, and acellular pertussis; HAV, Hepatitis A virus; Hib, Haemophilus influenzae type b; HBV, Hepatitis B virus; HPV, human papillomavirus; RNA, ribonucleic acid.
as illustrated in Figure 3. The main advantages of the gene-based platform include the construction of antigens directly from the genetic sequence of the desired protein and a generic manufacturing process, which allows for efficient production of different vaccines using the same established processes and facilities, given the genetic sequence is available.

Unlike conventional vaccine technologies, which consist of a lengthy process of inactivating or attenuating a live pathogen or making a recombinant protein, making a gene-based vaccine is relatively rapid and potentially low-risk, eliminating the need to work with a virulent pathogen during manufacturing. In addition, plasmid DNA and mRNA vaccine constructs encode only the antigen of interest, avoiding other redundant, potentially detrimental proteins and the replication of infectious viral particles.

However, since their initial presentation in 1990, there has never been a commercial vaccine utilizing gene-based technologies approved for use. There have been many technical challenges to overcome to enable the promise of the gene-based platform, including optimizing the delivery of these foreign nucleic acids into human cells and increasing the potency, stability, and expression of the encoded protein. These goals have been achieved by new formulations, including lipids, polymers, and novel delivery devices for improved intracellular delivery and stability, and strong molecular adjuvants for improved potency.

**DNA-based Vaccines** consist of antigen-encoding plasmids. While allowing a relatively simple, safe, and time-saving production process, the DNA-based platform poses several challenges related to administration, safety, and immunogenicity, as summarized in Table 2. Unlike DNA vaccines, mRNA-based vaccines translate directly into the cytoplasm, undergo natural degradation, and cannot integrate into the host genome. These advantages in terms of safety, efficacy, and manufacturing make the mRNA technology a promising avenue for a rapid response to the emerging COVID-19 pandemic, and are summarized, alongside the disadvantages, in Table 2.

**COVID-19 VACCINE DEVELOPMENT: CURRENT CLINICAL TRIALS**

Finding the most suitable target site for SARS-CoV-2 vaccine development is extremely important. The SARS-CoV-2 coronavirus belongs to the subfamily of Coronavirinae, with a genomic structure of (+) ss-RNA. Hoffman et al. described the SARS-CoV-2 cell entry and replication mechanisms in detail and Bouhaddou et al. recently demonstrated the role of virus-containing filopodia induced in host cells by SARS-CoV-2 in viral replication. Cell entry of SARS-CoV-2 is orchestrated by the viral spike (S) proteins, which give the virus its characteristic corona-like morphology, via binding the host cellular receptors. Due to its pivotal role, a vaccine against S protein can prevent SARS-CoV-2’s proliferation and spread.

As of August 14, 2020, there have been 29 vaccine candidates in clinical trials, as summarized in Table 3 and Figure 1. In total, 13 trials are currently in Phase 1, 8 in joint Phase 1/2, 2 in Phase 2 and 6 in Phase 3. An estimated 138 vaccine candidates are currently in preclinical studies. While 12 clinical trials are based on traditional techniques utilizing inactivated viruses (5 trials), and protein subunits (7 trials), 16 trials utilize novel platforms including the viral vector-based platform (6 trials), and gene-based platform (10 trials: 6 mRNA-based, 4 DNA-based). Current viral-vector-based and gene-based vaccines under development target the S protein of SARS-CoV-2.

**Viral-vector-based Clinical Trials**

Three viral-vector-based vaccines are currently under clinical trials (Table 3). The Adenovirus Type 5 Vector (Ad5-nCoV) and ChAdOx1 nCoV-19 trials are the furthest along in development and will be discussed below.

**Adenoviral Vectors of Human Origin: Ad5-nCoV**

Ad5-nCoV is a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the S protein of SARS-CoV-2. Ad5 is a non-replicating vector of human origin, and one of the most widely used adenoviral vectors. However, the widespread pre-existing immunity to Ad5 among the human population might hinder its immunogenicity and hamper its clinical use. Phase 1 results have recently been published, demonstrating that the Ad5 vectored COVID-19 vaccine was tolerable and immunogenic at 28 days post-vaccination. Most adverse reactions were mild or moderate in severity, with the most common adverse reactions being fever, fatigue, headache, and muscle pain. No serious adverse events were noted within 28 days post-vaccination. Neutralizing antibodies increased significantly at day 14, and peaked 28 days post-vaccination, while specific T-cell response peaked at day 14 after one administration of the vaccine. However, in patients with pre-existing anti-Ad5 immunity, both the specific antibody response and T-cell response induced by vaccination were diminished. The recently published Phase II results have confirmed Phase I results, demonstrating that the Ad5-vectored COVID-19 vaccine was safe, and induced significant immune responses in the majority of recipients after a single immunization. Phase III results are expected before the end of 2020.

**Adenoviral Vectors of Non-human Origin: ChAdOx1 nCoV-19 (AZD1222)**

Adenoviral vectors of non-human origin induce enhanced memory and more poly-functional CD8+ T cells compared with Ad5 and are less likely to be hampered by pre-existing immunity. ChAdOx1 nCoV-19 is a replication-deficient chimpanzee adenovirus expressing the S protein of SARS-CoV-2. Phase I/II results have recently been published, demonstrating an acceptable safety profile of ChAdOx1 nCoV-19 with no serious adverse events. The vaccine induced both humoral and cellular immune responses and all participants had neutralizing activity after a booster dose. Phase III is currently ongoing.
Table 3. Candidate Vaccines against SARS-CoV-2 Currently in Clinical Trials

| S. No. | Vaccine Name | Developer (Country) | Platform | Phase 1 Start Date (mm/dd/yyyy) | Current Phase | Participants' Age and Sample Size (N)* | Mode of Administration | Vaccination Schedule* | Same Platform for Other Viral Candidates |
|--------|--------------|---------------------|----------|---------------------------------|--------------|----------------------------------------|------------------------|------------------------|-----------------------------------------|
| 1      | N/A          | Beijing Institute of Biological Products and Sinopharm (China) | Inactivated | 04/28/2020 | Phase 3 (ChiCTR2000034780)  Phase 1/2 (ChiCTR2000032459)  Phase 1/2 (ChiCTR2000031809) | • Ages: 18 and over  • N = 15,000 | IM | Day 0, 14 or 0, 21 |                          |
| 2      | N/A          | Wuhan Institute of Biological Products and Sinopharm (China) | Inactivated | 04/11/2020 | Phase 3 (ChiCTR2000034780)  Phase 1/2 (ChiCTR2000031809) | • Ages: 18 and over  • N = 15,000 | IM | Day 0, 14 or 0, 21 |                          |
| 3      | PiCoVacc/PROFISCOV | Sinovac (China) | Inactivated | 04/16/2020 | Phase 3 (NCT04565955)  Phase 1/2 (NCT04383574)  Phase 1/2 (NCT04352608) | • Ages: 18 and over  • N = 8870 | IM | Day 0, 14 | SARS |                          |
| 4      | N/A          | Institute of Medical Biology, Chinese Academy of Medical Sciences (China) | Inactivated | 05/15/2020 | Phase 1/2 (NCT04470609)  Phase 1 (NCT04412538) | • Ages: 18 and over  • N = 942, 471 | IM | Day 0, 28 |                          |
| 5      | BBV152       | Bharat Biotech (India) | Inactivated | 07/13/2020 | Phase 1 (NCT04471519) | • Ages: 16–65  • N = 1125 | IM | Day 0, 14 |                          |
| 6      | ChAdOx1nCoV-19 (AZD1222) | University of Oxford and AstraZeneca (UK) | Viral vector (non-replicating) | 05/19/2020 | Phase 1/2 (ISRCTN89951424)  Phase 2b/3 (2020001228-32)  Phase 1/2 (2020-001072-15) | • Ages: 18–55  • N = 10,260; 30,000; 2000 | IM | Day 0 | MERS, influenza, TB, Chikungunya, Zika, MenB, plague |                          |
| 7      | Adenovirus Type 5 Vector (Ad5-nCoV) | CanSino Biological and Beijing Institute of Biotechnology (China) | Viral vector (non-replicating) | 03/16/2020 | Phase 2 (ChiCTR2000031781)  Phase 1 (ChiCTR2000030906) | • Ages: 18 and over  • N = 500 | IM | Day 0 | EBOV |                          |
| 8      | Gam-COVID-19Vacc | Gamaleya Research Institute (Russia) | Viral vector (non-replicating) | 06/17/2020 | Phase 1 (NCT04364171)  Phase 1 (NCT04387875)  Phase 1/2 (NCT0436276)  Phase 1 (2020-001072-15) | • Ages: 18–60  • N = 38 | IM | Day 0 |                          |
| 9      | Ad26COVS1 | Janssen Pharmaceutical Companies (USA, Belgium) Reithera/LEUKOCARE/Univercells (Italy, Germany, Belgium) | Viral vector (non-replicating) | 07/15/2020 | Phase 1 (NCT04471519)  Phase 1 (NCT04412538)  Phase 2a/3 (2020001228-32) | • Ages: 18–55  • N = 1045 | IM | Day 0, 56 |                          |
| 10     | N/A          | Institute Pasteur/Théramis/Univ. of Pittsburg VR/merck Sharp & Dohme (Belgium, France) | Viral vector (replicating) | 08/10/2020 | Phase 1 (NCT04497298) | • Ages: 18–55  • N = 90 | IM | Day 0, 28 |                          |
| 11     | COVID-19-101 | Institute Pasteur/Théramis/Univ. of Pittsburg VR/merck Sharp & Dohme (Belgium, France) | Viral vector (replicating) | 05/25/2020 | Phase 1 (NCT04368988)  Phase 1 (NCT04405908)  Phase 1 (NCT04466085)  Phase 1 (NCT0445194) | • Ages: 18–59  • N = 131 | IM | Day 0, 21 | RSV; CCHF, HPV, VZV, EBOV |                          |
| 12     | NVX-CoV2373 | Novavax (USA, Australia) | Protein subunit | 06/19/2020 | Phase 1 (NCT04405908)  Phase 1 (NCT04466085)  Phase 1 (NCT0445194) | • Ages: 18–59  • N = 900 | IM | Day 0, 28 | MERS |                          |
| 13     | SCB-201      | Clover Biopharmaceuticals Inc./Protein subunit | 05/28/2020 | Phase 1 (NCT04368988)  Phase 1 (NCT04405908)  Phase 1 (NCT04466085)  Phase 1 (NCT0445194) | • Ages: 18–59  • N = 131 | IM | Day 0, 21 | RSV, CCHF, HPV, VZV, EBOV |                          |
| 14     | N/A          | Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences (China) | Protein subunit | 06/22/2020 | Phase 1 (NCT04405908)  Phase 1 (NCT04466085)  Phase 1 (NCT0445194) | • Ages: 18–59  • N = 900 | IM | Day 0, 28 or 0, 28, 56 |                          |
| S. No. | Vaccine Name | Developer (Country) | Platform | Phase 1 Start Date (mm/dd/yyyy) | Current Phase | Participants' Age and Sample Size (N)* | Mode of Administration | Vaccination Schedule* | Same Platform for Other Viral Candidates |
|--------|--------------|---------------------|----------|-------------------------------|--------------|----------------------------------------|------------------------|-----------------------|----------------------------------------|
| 15     | COVAX19      | Vaxine Pty Ltd / Medytox (Australia) | Protein subunit | 06/30/2020 Phase 1 (NCT04453852) | □ Ages: 18–65 □ N = 40 | □ Ages: 18–70 □ N = 180 | IM | N/A |                                      |
| 16     | KBP 201      | Kentucky Bioprocessing, Inc (USA) | Protein subunit | 09/14/2020 Phase 1/2 (NCT04453852) | □ Ages: 18–55 □ N = 120 | □ Ages: 20–50 □ N = 45 | IM | Day 0, 21 |                                      |
| 17     | N/A          | University of Queensland / CSL/Covia (Australia) | Protein subunit | 07/13/2020 Phase 1 (ACTRN12620000674932p) | □ Ages: 18–55 □ N = 120 | □ Ages: 20–50 □ N = 45 | IM | Day 0, 28 |                                      |
| 18     | MVC-COV1901  | Medigen Vaccine Biologics Corporation / NIAID / Dynavax (Taiwan) | Protein subunit | 09/01/2020 Phase 1 (NCT04487210) | □ Ages: 18–50 □ N = 30 | □ Ages: 18–55 □ N = 180 | IM | Day 0, 28 | Multiple candidates |
| 19     | mRNA-1273    | Moderna and NIAID (USA) | mRNA | 05/16/2020 Phase 3 (NCT04470427) | □ Ages: 18 and over □ N = 30,000 | | IM | Day 0, 28 | Multiple candidates |
| 20     | BNT162       | BioNTech and Pfizer (Germany and USA) | mRNA | 04/29/2020 Phase 3 (NCT0448283641) | □ Ages: 18–85 □ N = 29,481 | | IM | Day 0, 28 |                                      |
| 21     | COVAC1       | Imperial College London (UK) | mRNA | 04/01/2020 Phase 1 (ISRCTN17072692) | □ Ages: 18–45 □ N = 320 | □ Ages: 18–60 □ N = 168 | IM | N/A | EBOV, LASV, MARV, Inf (H7N9), Rabies, Lassa, YFV, MERS, Influenza, Zika, Dengue, NPV |
| 22     | CVnCoV       | Curevac (Germany, Belgium) | mRNA | 06/18/2020 Phase 1 (NCT04492976) | □ Ages: 18–80 □ N = 168 | | IM | Day 0, 28 |                                      |
| 23     | N/A          | People’s Liberation Army (PLA) Academy of Military Sciences / Walvax Biotech (China) | mRNA | 06/25/2020 Phase 1 (ChiCTR2000034112) | □ Ages: 18–80 □ N = 168 | | IM | N/A |                                      |
| 24     | ARCT-021     | Arcturus/Duke-NUS (Singapore) | mRNA | 08/10/2020 Phase 1/2 (NCT04480957) | □ Ages: 21–80 □ N = 92 | □ Ages: 18 and over □ N = 120 | IM | Day 0, 14 or 0, 28 | Multiple candidates |
| 25     | INO-4800     | Inovio Pharmaceuticals (USA) | DNA | 04/03/2020 Phase 1/2 (NCT04336410) | □ Ages: 21–80 □ N = 92 | □ Ages: 18 and over □ N = 120 | ID | Day 0, 28 | Multiple candidates |
| 26     | nCov         | Cadila Healthcare Limited (India) | DNA | 07/04/2020 Phase 1/2 (CTR/2020/07/026352) | □ Ages: 18–55 □ N = 1084 | □ Ages: 18–50 □ N = 190 | ID | Day 0, 28, 56 |                                      |
| 27     | GX-19        | Geneonex Consortium (Korea) | DNA | 06/17/2020 Phase 1 (NCT04455899) | □ Ages: 20–65 □ N = 30 | □ Ages: 18–55 □ N = 190 | IM | Day 0, 28 |                                      |
| 28     | N/A          | Osaka University / AnGeS / TakaraDNA Bio (Japan) | N/A | 07/10/2020 Phase 1 (NCT04463472) | □ Ages: 18–55 □ N = 190 | | IM | Day 0, 21 |                                      |
| 29     | N/A          | Medicago Inc. (Quebec, Canada) | VLP | 07/10/2020 Phase 1 (NCT04450004) | □ Ages: 18–55 □ N = 190 | | IM | Day 0, 21 |                                      |

*Data reflect the most advanced clinical phase available.
No; number; N/A, not available; CCHF, Crimean-Congo Hemorrhagic Fever; DNA, Deoxyribonucleic acid; EBOV, Ebola virus; GMFR, Geometric mean fold rise; GMI, Geometric Mean Increase; GMR, Geometric Mean Ratio; GMT, Geometric Mean Titer; HPV, Human Papillomavirus; IFN-γ, Interferon gamma; IgG, Immunoglobulin G; IgM, Immunoglobulin M; LNP, Lipid nanoparticles; MARV, Marburg virus; Inf, influenza; MenB, Serogroup B Meningococcal; MERS, Middle East Respiratory Syndrome; mRNA, messenger ribonucleic acid; NIAID, National Institute of Allergy and Infectious Diseases; NPV, nuclear polyhedrosis virus; RNA, Ribonucleic acid; RSV, Respiratory syncytial virus; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TB, Tuberculosis; VZV, Varicella-zoster virus; YFV, Yellow fever virus.
in the UK, the USA, Brazil, and South Africa, and results are expected in the Fall of 2020.105,106

Gene-based Vaccines Clinical Trials

Totally, 4 DNA-based and 5 mRNA-based vaccines are currently in clinical trials (see Table 3). The mRNA-1273 trial is the furthest along in development and will be discussed below.

m-RNA-1273

mRNA-1273 developed in collaboration with the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH) is considered one of the frontrunners in vaccine development. The mRNA-1273 vaccine consists of mRNA of the S protein synthesized in vitro, and coated with lipid nanoparticles for effective delivery.

Phase I results have recently been published,86,102 demonstrating that mRNA-1273 was generally safe and well tolerated, with 1 incidence of a grade 3 adverse event (erythema around the injection site), and 3 incidences of grade 3 systemic symptoms (including fever, muscle pain and headache) seen at the highest dose group, only following the 2nd dose. All adverse events have been transient and self-resolving. No grade 4 adverse events or serious adverse events have been reported. Phase II is currently ongoing,103 and Phase III is expected to commence before the end of July 2020 in collaboration with the NIAID. Phase III results are expected before the end of 2020.102

LOOMING CHALLENGES OF COVID-19 VACCINE DEVELOPMENT

While the preliminary results of the discussed trials are encouraging, whether a vaccine generates the needed types of immune responses to result in protective efficacy is unknown and cannot be predicted by Phase 1 studies. There still remain significant questions and uncertainties as to clinical efficacy and effects of potential mutations on the vaccine’s immunogenicity and long-term efficacy, safety, and potential benefit for specific target populations.

Clinical Efficacy and Long-term Immunity

One of the main questions that arise is whether a COVID-19 vaccine would be able to provide immunity, when it is still uncertain whether previously infected patients are protected from reinfection.106-107 Research in other coronavirus species has shown that immunity may not be long-lasting, with 2–3 years of protection estimated from work with SARS and MERS.108,109

To date, there is no evidence for cases of SARS-CoV-2 reinfections,102 and preliminary evidence in humans110 and rhesus macaques111 suggests that acquired immunity may protect from future reinfection, at least temporarily110,112-113 with most patients who recovered from COVID-19 producing sufficient amounts of neutralizing antibodies to protect against reinfection. A recently reported case series also indicated sufficient neutralizing antibody titers in convalescent plasma to neutralize SARS-CoV-2 in 5 COVID-19 patients, who all recovered after treatment.114

While further research is needed to assess the benefits and risks of convalescent plasma therapy for people with COVID-19,115-117 these preliminary findings provide hope for the development of an effective vaccine against SARS-CoV-2.12 There have been few reports of post-recovery positive PCR tests performed in asymptomatic or mildly symptomatic patients, which could be explained as either false-negative results, prolonged viral clearance, and shedding or reinfection.106,107,115-117

Further points that need to be addressed to better understand the immune responses to SARS-CoV-2 and the optimal vaccine profile and administration regimens include the lack of correlation between antibody titer rates and clinical improvement, the durability of neutralizing antibodies, and their correlation with durable immunity.118,119 The current gaps in knowledge highlight the importance of inducing potent humoral and cellular immune responses as potentially generated by viral-vector-based and gene-based vaccines.

Potential mutations in the S protein may also affect the long-term efficacy of a vaccine. There has been direct evidence of functionally meaningful S protein mutations that appear to mediate a higher binding affinity when compared with previous SARS viruses.120 Therefore, it is difficult to ensure that the current novel vaccines targeting SARS-CoV-2 protein S could be used for a long term. This highlights the importance of a cost-effective platform that is able to produce different vaccines rapidly and safely using existing production processes and already established manufacturing infrastructure. This is one of the main potential strengths of the gene-based technology over the conventional vaccine development platforms.

Clinical Safety and Adverse Events

There have been previous reports of systemic reactions to mRNA, DNA, and viral-vectorized vaccines, including adverse reactions identified in the Ad5-nCoV105 and mRNA-1273 Phase 1 trials.89 These outcomes have raised concerns about the safety of these novel platforms. As previously discussed, one of the main concerns of utilizing mRNA-based platforms is the potential toxicity of synthetically formulated mRNA due to its inherent inflammatory nature.121 The use of DNA-based vaccines and viral-vector-based vaccines raises safety concerns due to their potential long-term persistence,121,122 genome integration,123,124 autoantibody generation, potential induction of anti-vector immunity,124 and adverse effects due to co-stimulatory molecule expression.125

These safety concerns cannot be fully investigated by pre-clinical studies because humans may respond differently than the animal models used in the pre-clinical safety testing.126 Therefore, it is of vital importance to fully characterize the potential risks of these novel platforms and adjust dosing schemes accordingly. This holds true especially for mRNA-based vaccines, where repeated administration (boosting) is needed for generating the desired neutralizing antibody titer levels.127

Clinical Benefit for Specific Target Populations

A major question that requires further investigation is whether the elderly and immunocompromised populations,
who experience higher clinical attack rates and a more severe clinical course,29 would be able to mount a sufficiently robust antibody response to provide immunity in response to the vaccine. Most current trials are designed to include healthy elderly participants as part of advanced clinical phases; however, safety and potential efficacy should be established to include immunocompromised patients.

CONCLUSIONS

In conclusion, the rapid development of an effective and safe vaccine has become the most promising way to control the COVID-19 pandemic. Over 20 candidate vaccines are in clinical trials and over 100 are in preclinical trials, utilizing both conventional and novel technologies. The viral-vector-based and gene-based vaccine technologies are promising novel platforms that have generated significant attention in recent years due to their potential use for a variety of applications. Their various advantages over conventional approaches highlight their role in the new era of vaccinology as potential game-changers in epidemics and emerging diseases. Once the fundamental key challenges have been addressed for viral-vector-based and gene-based vaccines, these novel technologies may become helpful in winning the fight against COVID-19 and in transforming the future of health care.

In the words of Louis Pasteur: In the field of observation, chance favors only the prepared mind.

Stav Brown, MD
Sackler School of Medicine
Tel Aviv University
35 Kliazin St,
Tel Aviv 69978, Israel
E-mail: brown.stav@gmail.com

REFERENCES
1. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
2. Coronavirus Research Center. COVID-19 Dashboard by The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Available at https://coronavirus.jhu.edu/map.html. Accessed June 11, 2020.
3. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control COVID-19. N Engl J Med. 2020;382:2158–2160.
4. Arons MM, Hatfield KM, Reddy SC, et al; Public Health–Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090.
5. Squiteri L, Chung KC. Surviving the COVID-19 pandemic: Surge capacity planning for nonemergent surgery. Plast Reconstr Surg. 2020;146:437–446.
6. Anderson RM, Heisterbeck H, Klinkenberg D, et al. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395:931–934.
7. Rohrich RJ, Hamilton KL, Avashia Y, et al. The COVID-19 pandemic: changing lives and lessons learned. Plast Reconstr Surg Glob Open. 2020;8:e2854.
8. Hollander JE, Carr BG. Virtually perfect? telemedicine for COVID-19. N Engl J Med. 2020;382:1679–1681.
9. Shokri T, Lighthall JG. Telemedicine in the era of the COVID-19 pandemic: Implications in facial plastic surgery. Facial Plast Surg Aesthet Med. 2020;22:155–156.
10. Sarac BA, Schoenbrunner AR, Wilson SC, et al. Coronavirus disease 2019 state guidelines on elective surgery: considerations for plastic and reconstructive surgeons. Plast Reconstr Surg Glob Open. 2020;8:e2904.
11. Schoenbrunner AR, Sarac BA, Janis JE. A summary of recommendations for plastic surgeons during the coronavirus disease 2019 outbreak. Plast Reconstr Surg Glob Open. 2020;8:e3039.
12. Taub PJ. Plastic surgeons in the time of a pandemic: thoughts from the front line. Plast Reconstr Surg. 2020;146:458–459.
13. Cho DY, Yu JL, Um GT, et al. The early effects of COVID-19 on plastic surgery residency training: the University of Washington experience. Plast Reconstr Surg. 2020;146:447–454.
14. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. Available at https://www.fda.gov/media/156238/download. Accessed June 25, 2020.
15. Assaad M, Habibullah NK, Butler CE. The impact of COVID-19 on clinical trials. Ann Surg. 2020;272:e222–e223.
16. Baden LR, Rubin EJ. COVID-19—the search for effective therapy. N Engl J Med. 2020;382:1851–1852.
17. Sheahan TF, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222.
18. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787–1799.
19. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5:Cd013600.
20. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7:ofaa105.
21. Xu S, Li Y. Beware of the second wave of COVID-19. Lancet. 2020;395:1321–1322.
22. Burton DR, Walker LM. Rational vaccine design in the time of COVID-19. Cell Host Microbe. 2020;27:695–698.
23. Jenner E. Dr. Jenner, on the vaccine inoculation. Med Phys J. 1800;5:502–505.
24. Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med. 2013;368:551–560.
25. Prough ES, Weenen TC, Commandeur H, et al. Risk in vaccine research and development quantified. PLoS One. 2013;8:e57755.
26. Clinical Trial-Related Terms. Grants and Funding. National Institute of Health (NIH). Available at https://grants.nih.gov/policy/clearance-trial-related-terms.html. Accessed June 22, 2020.
27. Clinical Trials Phases. National Institute of Health (NIH). Available at https://www.clinicaltrials.gov/ct2/help/glossary/phase. Accessed June 22, 2020.
28. Clinical Research. Food and Drug Administration (FDA). Available at https://www.fda.gov/patients/drug-development-process(step-3-clinical-research. Accessed June 22, 2020.
29. Centers for Disease Control and Prevention (CDC). Principles of Vaccination. Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/prinvac.html. Accessed July 12, 2020.
30. Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol. 2020;20:401–403.
31. Sewell HF, Agius RM, Kendrick D, et al. Vaccines, convalescent plasma, and monoclonal antibodies for COVID-19. BMJ. 2020;370:m2722.
32. Casadevall A, Joney MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA. 2020;324:455–457.
33. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:1–11.
34. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyper-immune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7:CD13600.

35. Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3:73–78.

36. Vaccines.gov. Vaccine Types. Available at https://www.vaccines.gov/basics/types. Accessed June 24, 2020.

37. Versteeg L, Almutairi MM, Hotez PJ, et al. Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines (Basel). 2019;7:122.

38. Zhang C, Maraggi G, Shan H, et al. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.

39. Naran K, Kundalall T, Chetty S, et al. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Front Microbiol. 2018;9:3158.

40. Pandey SC, Pande V, Sati D, et al. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020;256:117556.

41. Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1693.

42. Lurie N, Saville M, Hatchett R, et al. Developing COVID-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–1973.

43. Mascola JR, Fauzi AS. Novel vaccine technologies for the 21st century. Nat Rev Immunol. 2020;20:87–98.

44. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. By J Pharmacol. 2009;157:153–165.

45. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. By J Pharmacol. 2009;157:153–165.

46. Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4:43–65.

47. Lauer KB, Borrow R, Blanchard TJ. Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol. 2017;24:e00298–e00316.

48. Tan WG, Jin HT, West EE, et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol. 2013;87:1359–1372.

49. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Res. 2011;2011:62–84.

50. Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279.

51. Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of nanoparticles encapsulating barcoded mRNA for accelerated delivery screening. J Nanoparticle Res. 2020;22:4921700.

52. Reichmuth AM, Oberli MA, Jalkenev A, et al. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–334.

53. Weiss TJ, Scheiblhofer R, Sandra. Gene Vaccines. 2012.

54. Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019:7:37.

55. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468.

56. Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnostic applications of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39:1–7.

57. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.

58. Chen Y, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182:685–712.e19.

59. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.

60. World Health Organization. Draft Landscape of COVID-19 Candidate Vaccines. Available at https://www.who.int/publications/m/item/draft-landscape-of-Covid-19-candidate-vaccines. Accessed June 9, 2020.

61. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9:776–788.

62. Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39:1–7.

63. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.

64. woman Dodd M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182:685–712.e19.

65. Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.e6.

66. Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;39:1–7.

67. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.

68. Chinese Clinical Trials Register. A Phase I/II Clinical Trial for Inactivated Novel Coronavirus (2019-nCoV) Vaccine (Vero cells). Registration number: ChiCTR2000032459. Available at http://www.chictr.org.cn/showproj.aspx?proj=53005. Accessed June 9, 2020.

69. Chinese Clinical Trials Register. A Randomized, Double-blind, Placebo-Parallel-controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells). Registration number: ChiCTR2000031809. Available at http://www.chictr.org.cn/showproj.aspx?proj=52227. Accessed June 9, 2020.

70. U.S. National Library of Medicine. Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19). ClinicalTrials.gov Identifier: NCT04383574. Available at https://clinicaltrials.gov/ct2/show/NCT04383574?term=covid-19&cond=vaccine&cntry=CN&draw=2. Accessed June 9, 2020.

71. U.S. National Library of Medicine. Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. ClinicalTrials.gov Identifier: NCT04412538. Available at https://clinicaltrials.gov/ct2/show/NCT04412538?term=vaccine&cond=covid-19&draw=2. Accessed June 9, 2020.

72. U.S. National Library of Medicine. Clinical Trial of Efficacy and Safety of Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2&rank=1. Accessed July 12, 2020.

73. U.S. National Library of Medicine. Who-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152). Available at https://clinicaltrials.gov/ct2/show/NCT04471519?term=bharat&cond=covid-19&draw=2&rank=1. Accessed August 13, 2020.

74. U.S. National Library of Medicine. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine with/without Matrix-M Adjuvant. ClinicalTrials.gov Identifier: NCT04368988. Available at https://clinicaltrials.gov/ct2/show/NCT04368988?term=vaccine&recr=a&cond=covid-19&draw=2. Accessed June 9, 2020.

75. ClinicalTrials.gov. SCB-2019 as COVID-19 Vaccine. Available at https://clinicaltrials.gov/ct2/show/NCT04445194?term=longcom&draw=2. Accessed July 12, 2020.
87. Study to Describe the Safety, Tolerability, Immunogenicity, and Safety, Tolerability and Immunogenicity of INO-4800 for
86. Dose-Confirmation Study
85. A Study of Ad26.COV2.S in
84. ISRCTNRegistry. A phase III study to investigate a vaccine
83. Chinese Clinical Trials Register. A Randomized, Double-blinded,
82. Chinese Clinical Trials Register. Placebo-controlled Phase II Clinical Trial for Recombinant Novel Coronavirus (2019-nCoV) (Adenovirus Vector).
Registration number: ChiCTR2000031781. Available at http://www.chictr.org.cn/showprojen.aspx?proj=52006. Accessed June 9, 2020.
81. Chinese Clinical Trials Register. A Phase I Clinical Trial for Recombinant Novel Coronavirus (2019-COV) Vaccine (adenoviral vector). Registration number: ChiCTR2000030906. Available at http://www.chictr.org.cn/showprojen.aspx?proj=51154. Accessed June 9, 2020.
80. U.S. National Library of Medicine. An Open Study of the Safety, Tolerance and Safety, Tolerability and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19. EudraCT number: 2020-001072-15. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2020/001072-15/GB. Accessed June 9, 2020.
79. Chinese Clinical Trials Register. A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers. EudraCT number: 2020-001228-32. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2020/001228-32/GB. Accessed June 9, 2020.
110. Batisse D, Benech N, Botelho-Nevers E, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? *J infect.* 2020.

111. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science.* 2020;369:812–817.

112. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med.* 2020;26:845–848.

113. Watson J, Whiting PF, Brush JE. Interpreting a COVID-19 test result. *BMJ.* 2020;369:m1808.

114. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA.* 2020;323:1582–1589.

115. Xing Y, Mo P, Xiao Y, et al. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. *Euro Surveill.* 2020;25:2000191.

116. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. *J Med Virol.* 2020;10.1002/jmv.25855.

117. Kang H, Wang Y, Tong Z, et al. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: persistence, sampling issues, or re-infection? *J Med Virol.* 2020;10.1002/jmv.26114.

118. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20:565–574.

119. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-19. *Nature.* 2020;581:465–469.

120. Ortega JT, Serrano ML, Pujol FH, et al. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. *Excli J.* 2020;19:410–417.

121. Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adenovirus-associated virus injection into the nonhuman primate muscle. *Mol Ther.* 2001;4:559–566.

122. Armengol G, Ruiz LM, Orduz S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. *Mol Biotechnol.* 2004;27:109–118.

123. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. *Gene Ther.* 2004;11:711–721.

124. Ura T, Okada K, Shimada M. Developments in viral vector-based vaccines. *Vaccines (Basel).* 2014;2:624–641.

125. Fló J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules. *Immunology.* 2000;100:259–267.

126. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. *Lancet.* 2017;390:1511–1520.

127. Schlake T, Thess A, Thran M, et al. mRNA as novel technology for passive immunotherapy. *Cell Mol Life Sci.* 2019;76:301–328.

128. Lithander FE, Neumann S, Tenison E, et al. COVID-19 in older people: a rapid clinical review. *Age Ageing.* 2020;49:501–515.